Guselkumab Efficacy in Psoriasis: Key Findings from VOYAGE Studies
Background
The VOYAGE 1 and VOYAGE 2 studies showed that guselkumab is effective and safe for treating moderate-to-severe psoriasis for up to 5 years. This analysis looked at how effective guselkumab is based on the severity of the disease and previous treatments.
Methods
Patients were divided into groups to receive either guselkumab, a placebo, or adalimumab, with some switching to guselkumab later. All patients received guselkumab for a total of 252 weeks. The study evaluated treatment responses based on different severity levels and treatment histories.
Results
Across all time points from weeks 100 to 252, the effectiveness of guselkumab was consistent regardless of:
- Baseline PASI: Similar response rates for patients with PASI <20 and ≥20.
- Investigator’s Global Assessment: Comparable outcomes for IGA scores of 3 and 4.
- Body Surface Area: Consistent results for BSA <20% and ≥20%.
- Prior Treatments: No significant differences based on previous phototherapy, nonbiologic, or biologic treatments.
Conclusions
Guselkumab maintained its effectiveness over 5 years for all patient groups, regardless of disease severity or treatment history.
Practical Solutions for Clinicians
Clinical trials are essential for developing safe treatments. To make these findings useful in everyday practice, we offer:
- DocSym: An AI-driven platform that combines ICD-11 standards, clinical protocols, and research for easy access.
- Mobile Apps: Tools for scheduling, monitoring treatments, and telemedicine to enhance patient care.
- AI Integration: Streamlining workflows to improve patient outcomes and reduce paperwork.
Learn more about how we can assist you at aidevmd.com.
